MedTrace Logo

Hypoxic Pulmonary Vasoconstriction Pilot Study

NCT03733470 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-10-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the events leading to smoking-associated centrilobular and paraseptal emphysema are caused by a failure of the lungs' inherent mechanisms to block hypoxic pulmonary vasoconstriction (HPV) in areas of smoking-induced inflammation.

Conditions

  • Emphysema

Interventions

DRUG

Sildenafil study group

One dose of 20 mg Sildenafil will be given one hour before CT imaging.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Eric A. Hoffman

    lead OTHER

Principal Investigators

  • Eric A Hoffman · University of Iowa

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-29
Primary Completion
2014-01-13
Completion
2014-01-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03733470 on ClinicalTrials.gov